Vanguard Group
HOWL icon

Vanguard Group’s Werewolf Therapeutics HOWL Stock Holding History

Vanguard Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$893K Hold
1,408,047
– – ﹤0.01% 3809
2025
Q3 		$2.77M Buy
1,408,047
+109,796
+8% +$150K ﹤0.01% 3472
2025
Q2 		$1.42M Sell
1,298,251
-211,185
-14% -$217K ﹤0.01% 3646
2025
Q1 		$1.47M Buy
1,509,436
+88,467
+6% +$116K ﹤0.01% 3593
2024
Q4 		$2.1M Buy
1,420,969
+5,439
+0.4% +$11.1K ﹤0.01% 3548
2024
Q3 		$3M Buy
1,415,530
+91,749
+7% +$209K ﹤0.01% 3441
2024
Q2 		$3.23M Buy
1,323,781
+216,434
+20% +$1.04M ﹤0.01% 3413
2024
Q1 		$7.18M Buy
1,107,347
+233,909
+27% +$1.36M ﹤0.01% 3138
2023
Q4 		$3.37M Buy
873,438
+325,787
+59% +$832K ﹤0.01% 3426
2023
Q3 		$1.17M Buy
547,651
+83,737
+18% +$231K ﹤0.01% 3773
2023
Q2 		$1.41M Hold
463,914
– – ﹤0.01% 3786
2023
Q1 		$1.21M Buy
463,914
+14,987
+3% +$44.7K ﹤0.01% 3859
2022
Q4 		$920K Buy
448,927
+13,671
+3% +$35.8K ﹤0.01% 3935
2022
Q3 		$1.96M Buy
435,256
+39,187
+10% +$213K ﹤0.01% 3750
2022
Q2 		$1.62M Sell
396,069
-126,018
-24% -$575K ﹤0.01% 3900
2022
Q1 		$2.3M Sell
522,087
-5,458
-1% -$38.2K ﹤0.01% 3901
2021
Q4 		$6.28M Buy
527,545
+357,280
+210% +$5.39M ﹤0.01% 3488
2021
Q3 		$2.92M Sell
170,265
-2,862
-2% -$48.8K ﹤0.01% 3926
2021
Q2 		$3.02M Buy
+173,127
New +$2.37M ﹤0.01% 3834

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group's HOWL Position: Q4 2025 in Review

Vanguard Group held its Werewolf Therapeutics (HOWL) position steady in Q4 2025 at 1,408,047 shares worth $893K. The position accounts for ﹤0.01% of the portfolio, ranked #3809.

Vanguard Group first reported a position in HOWL in Q2 2021 and has held it in 19 quarters since. The position peaked at $7.18M in Q1 2024. 51 funds tracked by Wall St. Rank hold HOWL as of Q4 2025.

  • Vanguard Group held 1,408,047 shares of Werewolf Therapeutics worth $893K as of Q4 2025.
  • Vanguard Group left its Werewolf Therapeutics share count unchanged in Q4 2025.
  • Werewolf Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3809 holding.
  • Vanguard Group first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Vanguard Group's Werewolf Therapeutics position peaked at $7.18M in Q1 2024.
  • 51 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.